Duke University Medical Center is conducting a research study to evaluate the antiviral
efficacy, safety, and tolerability of GS-7977 with RBV for the treatment of chronic HCV
in subjects who are co-infected with HIV.

Eligibility Criteria
To participate in this study, you must be an adult who meets the following criteria:
• Has hepatitis C genotype 1, 2 or 3; treatment naïve and treatment experienced; coinfected
with HIV-1
• Screening laboratory values, test, and physical exam within acceptable ranges

Duration
Your participation could last up to 52 weeks.

For more information, contact April Seward at 919-681-8852 or 866-704-4673.

For more information, contact Heather Kuehn at 668-1681.